Literature DB >> 7107024

[Binding, distribution and efficacy of erythromycin (author's transl)].

G A Dette.   

Abstract

The significance of the binding of antibiotics in humans in still a controversial question. In principle, only free, unbound antibiotic is considered to be diffusible and biologically active. With unimpaired measurements and a binding balance within the normal therapeutic concentration range, the free portion of erythromycin in the human serum is found to depend significantly on the total concentration of erythromycin. For example, for concentrations of 1, 16 and 24 mg/l, approx. 74%, 54% and 46% are bound (+38 degrees C). binding is temperature-dependent and decreases with decreasing temperature. At +4 degrees C, 44% of 1 mg/l and 30% of 16 mg/l are bound. These binding characteristics are based in part on the properties of erythromycin's major binding partner in the serum - acidic alpha1-glycoprotein. Albumin only contributes slightly to the overall binding and is not concentration-dependent in the therapeutic range, i.e. it cannot be saturated. Binding phenomena have a decisive influence on the distribution of an antibiotic within an organism. In the case of erythromycin, the tissue levels in nearly every organ are higher, sometimes considerably higher, than the corresponding serum levels. We have shown the binding of erythromycin to cytosol and particle fractions in certain organs and compared this to the binding in the serum. The antibacterial principle regarding the efficacy of erythromycin is also based primarily on a binding reaction which maintains the concentration gradient for the intake of erythromycin in microorganisms. The kinetics ofintake (microorganism) are compared to those of binding (macroorganism) and referred to the minimum inhibitory concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107024     DOI: 10.1007/BF01640863

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Behaviour in vitro of some new antistaphylococcal antibiotics.

Authors:  L P GARROD; P M WATERWORTH
Journal:  Br Med J       Date:  1956-07-14

2.  THE BINDING OF SULFONAMIDE DRUGS BY PLASMA PROTEINS. A FACTOR IN DETERMINING THE DISTRIBUTION OF DRUGS IN THE BODY.

Authors:  B D Davis
Journal:  J Clin Invest       Date:  1943-09       Impact factor: 14.808

3.  Erythromycin stearate in acute maxillary sinusitis.

Authors:  O Kalm; C Kamme; B Bergström; T Löfkvist; O Norman
Journal:  Scand J Infect Dis       Date:  1975

4.  Standardization of a preparative ultracentrifuge method for quantitative determination or protein binding of seven antibiotics.

Authors:  L R Peterson; W H Hall; H H Zinneman; D N Gerding
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

5.  Serum protein binding of erythromycin and erythromycin 2'-propionate ester.

Authors:  R G Wiegand; A H Chun
Journal:  J Pharm Sci       Date:  1972-03       Impact factor: 3.534

6.  Serum unbound levels of cloxacillin and erythromycin in cystic fibrosis.

Authors:  H B Valman; K E Evans
Journal:  Arch Dis Child       Date:  1970-10       Impact factor: 3.791

7.  [Tissue penetration of erythromycin (author's transl)].

Authors:  G A Dette
Journal:  Infection       Date:  1979       Impact factor: 3.553

8.  Binding of [14C]erythromycin to Escherichia coli ribosomes.

Authors:  S Pestka
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

9.  Pharmacokinetics of intravenous erythromycin.

Authors:  P G Welling; W A Craig
Journal:  J Pharm Sci       Date:  1978-08       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.